Eloralintide 10mg Pen – Research Peptide UK

Eloralintide 10mg Pen from N&A Peptides is a research peptide presentation containing a nominal 10mg quantity of Eloralintide (LY3841136), an investigational selective amylin receptor agonist developed by Eli Lilly. Eloralintide is attracting scientific interest for its interaction with the amylin receptor system, particularly the AMY1 receptor. This signalling pathway is being investigated in relation to metabolic regulation, satiety and energy homeostasis. Our Eloralintide 10mg Pen is presented for laboratory and analytical research purposes only. It is not an approved medicine and is not intended for human or veterinary administration.

Eloralintide 10mg Pen – Product Specifications

• Product: Eloralintide 10mg Pen
• Compound: Eloralintide
• Research identifier: LY3841136
• Nominal quantity: 10mg
• Presentation: Research pen
• Classification: Investigational selective amylin receptor agonist
• Primary research interest: AMY1 receptor signalling
• Research applications: Laboratory and analytical investigations
• Supplier: N&A Peptides UK

What Is Eloralintide?

Eloralintide is an investigational peptide designed to activate amylin receptors selectively. Amylin is a naturally occurring peptide hormone released alongside insulin by pancreatic beta cells. Amylin participates in physiological processes involving nutrient intake, satiety signalling and metabolic regulation. Researchers are studying how selective amylin receptor activation influences these biological pathways and how this mechanism differs from other investigational metabolic compounds. Unlike GLP-1 receptor agonists, eloralintide primarily targets the amylin receptor system, making it scientifically distinct from compounds acting through incretin pathways.

Eloralintide and AMY1 Receptor Research

One of the principal areas of scientific interest surrounding eloralintide is its preferential activity at the AMY1 receptor. Laboratory and clinical research involving selective amylin receptor agonists examines several important areas:

• AMY1 receptor activation and selectivity
• Amylin-mediated cellular signalling
• Satiety-associated biological pathways
• Metabolic hormone communication
• Energy homeostasis and nutrient regulation
• Interactions between amylin and incretin receptor systems

Understanding these mechanisms may help researchers characterise the wider role of amylin signalling in metabolic physiology.

Eloralintide Clinical Research

Eloralintide has undergone clinical investigation, including a Phase 2 study examining the compound in adults with obesity or overweight and an associated health condition. The 48-week study included 263 participants and investigated several experimental treatment regimens under controlled clinical conditions. Published research reported dose-dependent changes in body weight alongside safety and tolerability findings. The results supported continued investigation of the compound in Phase 3 clinical development. These results relate specifically to the investigational pharmaceutical preparation administered in clinical trials. They do not establish equivalent effects, safety or suitability for independently supplied research products. Read the scientific publication: Eloralintide Phase 2 Clinical Research – PubMed

Eloralintide Compared With Retatrutide

Eloralintide and retatrutide are both investigational peptides studied in metabolic research, but they act through different receptor systems.

Eloralintide – Selective Amylin Receptor Agonist

Eloralintide is designed to activate amylin receptors, with preferential activity at AMY1 receptors. Research focuses on amylin-mediated signalling and associated metabolic processes.

Retatrutide – Triple Receptor Agonist

Retatrutide is an investigational compound targeting GLP-1, GIP and glucagon receptors. Its mechanism is distinct from selective amylin receptor activation. Both compounds are subjects of ongoing scientific investigation. Their different mechanisms provide opportunities for research into multiple metabolic signalling pathways. Explore more scientific information through the N&A Peptides Research Guides.

Eloralintide 10mg Research Pen Presentation

The Eloralintide 10mg Pen features a clearly identified research compound and nominal quantity in a pen-style presentation. Accurate labelling and product identification are important for laboratory inventory management, sample traceability and research documentation. Researchers should confirm batch-specific analytical information before incorporating any research material into experimental protocols.

Research Quality and Analytical Documentation

At N&A Peptides, we recognise the importance of product identification, analytical documentation and transparency in scientific research. Where available, a Certificate of Analysis (COA) can provide information about the tested batch, including reported compound identity, purity and analytical results. Laboratory techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) are commonly used in peptide analysis. Any claims regarding batch purity, concentration or independent testing should be verified against the documentation accompanying the specific product.

Storage and Laboratory Handling

Research peptides should be stored and handled according to the requirements documented for the specific supplied batch.

• Follow the applicable batch-specific storage instructions.
• Maintain accurate laboratory sample records.
• Keep research materials clearly labelled.
• Protect samples from unsuitable environmental conditions.
• Restrict handling to appropriately qualified personnel.

Further Eloralintide Scientific Information

Researchers seeking additional information about eloralintide and amylin receptor agonism can consult the following resources:

• Eli Lilly – Eloralintide Research Overview
• PubMed – Eloralintide Phase 2 Study
• N&A Peptides – Research Guides
• N&A Peptides – Research Product Collection

Important Research Disclaimer

Eloralintide 10mg Pen is supplied strictly for laboratory, analytical and scientific research purposes only. NOT FOR HUMAN OR VETERINARY CONSUMPTION. Eloralintide is an investigational compound and is not an approved medicine. This product is not intended for the diagnosis, treatment, prevention or management of any medical condition. Clinical research information is included for scientific and educational context only and does not constitute medical advice, administration guidance or evidence of equivalence between this research material and clinical trial formulations.